- Oct. 18, 2016
-- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women's cancers, announced today that Timothy P. Coleman, Chairman and Chief Executive Officer, will present a corporate overview and update at the 5th
Annual McDermott Pharmaceutical/
Medtech Dealmaking Symposium on October 25 at LeMeredien Cambridge-MIT in Cambridge, Massachusetts.About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women's cancers. Nemucore's most advanced candidate NMI-900, is a "best-in-class"
therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in the first half of 2017. NMI-900's mechanism of action targets an important genetic network identified in difficult-to-
treat oncology indications such as triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). Of these indications, an additional two will be selected for clinical development starting in late 2017 or early 2018. For more information, please visit our website at http://www.Nemucore.com
.About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.About the Event
McDermott Will & Emery's fifth annual Pharmaceutical/
Medtech Dealmaking Symposium is the premier networking event for dealmakers at all levels of the pharmaceutical, biotechnology and medical technology life cycle. Dealmakers, C-suite executives, private equity and venture capital investors, and their counsel and advisors doing deals in this space will gather to share experiences and opportunities.